Investigational drug · Phase 3
Mevrometostat
Also called: PF-06821497
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
7
Any phase or sponsor naming "Mevrometostat"
First trial start
2024
Oct 21, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Mevrometostat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Castration Sensitive Prostate Cancer (mCSPC)
- Hormone Sensitive Prostate Cancer
- Prostate Cancer
- Cancer of the Prostate
- Metastatic Castration-Resistant Prostate Cancer
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Mevrometostat" as an intervention, largest first.
- This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07028853 · 1,000 participants (planned) · Start Sep 28, 2025 · Primary completion Sep 12, 2028
Drug: Mevrometostat; Placebo and 1 more · For: Metastatic Castration Sensitive Prostate Cancer (mCSPC); Hormone Sensitive Prostate Cancer; Prostate Cancer and 1 more
Sites: Huntsville, Alabama; Chandler, Arizona; Gilbert, Arizona · 319 sites in all
- A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.Pivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT06629779 · 900 participants (planned) · Start Oct 22, 2024 · Primary completion Sep 30, 2027
Drug: PF-06821497; Placebo and 1 more · For: Metastatic Castration-Resistant Prostate Cancer
Sites: Chandler, Arizona; Gilbert, Arizona; Glendale, Arizona · 203 sites in all
- A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).Pivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT06551324 · 609 participants · Start Oct 21, 2024 · Primary completion Feb 28, 2027
Drug: PF-06821497; Docetaxel and 1 more · For: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Sites: Homewood, Alabama; Chandler, Arizona; Gilbert, Arizona · 224 sites in all
- A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)Pivotal-lookingRecruiting
ORIC PharmaceuticalsIndustry
NCT07723248 · 600 participants (planned) · Start Aug 3, 2026 · Primary completion Mar 2028
Drug: Rinzimetostat; Darolutamide and 2 more · For: Metastatic Castration Resistant Prostate Cancer
Sites: Glendale, California; Coral Springs, Florida; Jeffersonville, Indiana · 15 sites in all
- A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT03460977 · 453 participants (planned) · Start Apr 17, 2018 · Primary completion Apr 20, 2028
Drug: Mevrometostat (PF-06821497); Enzalutamide and 1 more · For: Metastatic Castration Resistant Prostate Cancer (mCRPC); Small Cell Lung Cancer (SCLC); Follicular Lymphoma (FL)
Sites: Tucson, Arizona; Anaheim, California; Duarte, California · 84 sites in all
- A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor TherapyNot yet recruiting
Prostate Cancer Clinical Trials ConsortiumAcademic, hospital or other
NCT07592910 · 60 participants (planned) · Start Aug 2026 · Primary completion May 2029
Drug: Mevrometostat; Enzalutamide · For: Metastatic Castrate Resistant Prostate Cancer (mCRPC); Prostate Cancer (Adenocarcinoma)
PfizerPfizer (PFE)
NCT06661694 · 0 participants · Start Apr 28, 2025 · Primary completion Sep 8, 2025
Drug: Treatment A; Treatment B and 2 more · For: Healthy
Sites: Brussels, Belgium
Newest research
PubMed records naming it or its code names, newest first.
- Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols.
Shore ND, Fizazi K, Schweizer MT, et al. · Future Oncol 2026
- EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
Zhang Y, Zhou L, Safran H, et al. · Neoplasia 2021
- Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497).
Kung PP, Bingham P, Brooun A, et al. · J Med Chem 2018
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.